Invex Therapeutics (ASX:IXC) ROCE % : -37.53% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Invex Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -37.53%.

Invex Therapeutics ROCE % Historical Data

The historical data trend for Invex Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics ROCE % Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

ROCE %

-13.97

-8.65

-14.01

-36.12

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-12.89	-15.06	-34.90	-37.73	-37.53

Invex Therapeutics ROCE % Calculation

Invex Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-8.979	/	( ( (29.485 - 1.004)	+	(22.804 - 1.572) )	/ 2 )
	=	-8.979	/	( (28.481	+	21.232)	/ 2 )
	=	-8.979	/	24.8565
	=	-36.12 %

Invex Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-4.978	/	( ( (22.804 - 1.572)	+	(6.28 - 0.985) )	/ 2 )
	=	-4.978	/	( ( 21.232	+	5.295 )	/ 2 )
	=	-4.978	/	13.2635
	=	-37.53 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Invex Therapeutics (ASX:IXC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Invex Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.